NCT03911557 2025-11-12
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
University of Kentucky
Phase 2 Completed
University of Kentucky
GlaxoSmithKline
AstraZeneca
National Institutes of Health Clinical Center (CC)
MedImmune LLC